Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests

Table 3 Mutated oligonucleotides for site direct mutagenesis

oligo	forward	reverse
ECOR1_RWARD	GCAGAGCTCGTTTAGTGAACCGTCAGAATT
XHO1_REVERSE		CTGTTCAGGAAACAGCTATGACCGCGGCCG
A230T	GCGAAATTTTA CTGACATTGATGATTCCTGG	CAATGTCAGT AAAATTTCGCCAGTGATTGC
E341D	AAGTGTGGGAT CGACCTCTCTCAGGCTTAGC	GAGAGGTCGA TCCCACACTTCAAAGTTGTCTC
L310F	AGCCAAAGCTT TCCTTCAGGATAAGGACGTA	CCTGAAGGAA AGCTTTGGCTTGAGGGCTGA
V269M	GATATGTTAA TGATTGGCAACTTTGGCCTC	TTGCCAATCAT TAACATATCTGGGTCATTCC
T410A	ATAAATCCCG CAGGCACTGTTTTGCTTCAG	ACAGTGCCTGC GGGATTTATGTGACTTCTTA
L300F	TCTAATGACT TCCGACACATCAGCCCTCAA	GATGTGTCGGAA GTCATTAGACATGAATAAAG
R301P	TGACCTCCC ACACATCAGCCCTCAAGCCA	GGCTGATGTGTG GGAGGTCATTAGACATGAAT
D244H	GTATCTTGC ACTGGACATCTTTTAACCAG	GATGTCCAGTG CAAGATACTCTTTATACTTT
Q280K	CTGGAATCAGA AAGTAACTCAGATGGCCCTC	TGAGTTACTTT CTGATTCCAGCTGAGGCCAA

Underlined bases correspond to the mispairings with the normal alpha-galactosidase sequence used to introduce the mutations in the pCMV6-AC-AGAL vector

ISSN: 1750-1172